Comments
Drug major Cadila Healthcare Ltd (Zydus Cadila) on Tuesday said it has received final approval from the USFDA to Bupropion Hydrochloride Extended-release tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment, according to a company release here. The estimated sales in 2013, as per IMS, for this product were $255.9 million. The total market for Bupropion is estimated at $526.7 million. The group has 87 approvals and has filed 216 ANDAs since the commencement of filing process in FY 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.